Biogen Idec Says Long-Lasting Hemophilia Drug Meets Safety Goals

Before you go, we thought you'd like these...
Before you go close icon
Biogen Idec (BIIB) and Swedish Orphan Biovitrum said a potential hemophilia B treatment has metsafety goals in an early-stage study.

The study involved 14 previously treated patients, and the data showed that the drug, rFIXFc, was well tolerated and demonstrated an approximately three-fold increase in half-life, compared to previous data for existing therapies. That would give provide prolonged protection with a single dose.

The study was presented at the World Federation of Hemophilia Congress in Buenos Aires, Argentina, on July 11, 2010. Based on this study, the companies said they'll conduct a global registrational trial of the safety and effectiveness of the drug with 75 patients.

Hemophilia is a rare, inherited disorder in which patients have an impaired ability for blood clotting, leading to excessive bleeding. Current treatments require intravenous injections twice a week. This drug, the companies hope, would reduce the injections to once a week.

Read Full Story

Markets

S&P 500 2,204.71 12.76 0.58%
DJIA 19,216.24 45.82 0.24%
NASDAQ 5,308.89 53.24 1.01%
DAX 10,684.83 171.48 1.63%
HANG SENG 22,699.57 194.02 0.86%
NIKKEI 225 18,327.96 52.97 0.29%
USD (per EUR) 1.08 0.00 -0.01%
USD (per CHF) 1.01 0.00 0.02%
JPY (per USD) 113.74 -0.12 -0.10%
GBP (per USD) 1.27 0.00 0.13%

From Our Partners